hepatocellular carcinoma

  •   George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  •   George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

    .

  •   George Lundberg, MD

    This scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.

    .

  •   George Lundberg, MD

    This scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.

    .

  •   George Lundberg, MD

    Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

    In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.